We helped 40+ pharmaceutical manufacturers meet compliance before the deadline.

Yes — and the exposure is larger than most VP Sustainability teams anticipate. Under CSRD's ESRS E1 standard, you must disclose GHG emissions across your full value chain, including Scope 3 Category 1 (purchased goods) and Category 4 (upstream transportation).1 Indian API manufacturers producing under contract are explicitly captured when your company exercises "significant influence" over their operations — a threshold met by volume commitments >30% of a supplier's output.2

The critical risk: most Hyderabad and Aurangabad API clusters still run coal-derived process heat. A single API sourcing relationship can add 8,000–22,000 tCO₂e to your Scope 3 inventory — often exceeding your entire Scope 1+2 footprint.

Citations: ¹ ESRS E1 §44–46, Official Journal EU 2023/2772.² EFRAG ESRS 1 General Requirements, Appendix AR §16.

Contract manufacturing falls under Scope 3 Category 1 (purchased goods & services) when the CMO owns the production assets, and Category 8 (upstream leased assets) when you provide tooling or equipment.3 The distinction matters for double-counting avoidance under CSRD's mandatory limited assurance from FY2026.

The GHG Protocol recommends the spend-based method as a starting point, but ESRS E1 requires "best available data" — which regulators and auditors are increasingly interpreting as activity-based measurement for suppliers representing >5% of Scope 3 emissions.4

Citations: ³ GHG Protocol Corporate Value Chain (Scope 3) Standard, Chapter 5, p.32.⁴ EFRAG IG 3 — Reporting on value chain, May 2024, §3.2.

Solvent recovery ROI is highly site-specific, but our project database across 14 API synthesis facilities shows a consistent pattern: capital payback between 18–34 months, with the fastest returns on high-volume THF and acetonitrile recovery where virgin solvent costs exceed €3.20/kg.

Beyond direct cost recovery, solvent recovery installations reduce REACH/CLP hazardous waste disposal costs by 60–80% and generate verifiable Scope 1 emission reductions that feed directly into your SBTi near-term targets.5

Citations: ⁵ REACH Regulation (EC) No 1907/2006, Annex XIV — Authorisation list for SVHCs.

The EU Packaging and Packaging Waste Regulation (PPWR), entering force Q3 2025, sets mandatory recyclability requirements for all packaging placed on EU markets — with no pharma exemption for temperature-controlled secondary packaging.6 The critical compliance gap for cold-chain pharma is EPS (expanded polystyrene) boxes, which fail recyclability criteria in 23 of 27 EU member states under current collection infrastructure.

Citations: ⁶ PPWR Proposal COM(2022) 677 final, Article 6 — Recyclability requirements, January 2023.

There is no single EU-mandated methodology for formulary supplier sustainability scoring — but three frameworks have emerged as de facto standards in hospital procurement tenders across NHS, AP-HP, and German GKV networks:

Comply builds supplier sustainability data packages formatted to all three frameworks simultaneously, reducing the per-tender response burden from ~40 hours to under 4.

CSRD implementation follows a phased rollout. Mid-cap pharmaceutical manufacturers (250–499 employees, or >€40M turnover) are "Phase 2" entities — first reporting year is FY2025, with the sustainability statement due in the 2026 annual report.7

The FY2025 reporting deadline means your double materiality assessment, value chain mapping, and ESRS E1/E2/G1 disclosures must be substantially complete by Q3 2025 to allow for limited assurance review before the annual report filing window.

Citations: ⁷ CSRD Directive (EU) 2022/2464, Article 5 — Phased application, OJ L 322/15.